BioStem Technologies, Inc. (OTCMKTS:BSEM – Get Free Report) was the target of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 63,500 shares, an increase of 25.7% from the July 15th total of 50,500 shares. Based on an average daily volume of 35,700 shares, the short-interest ratio is currently 1.8 days.
BioStem Technologies Stock Performance
Shares of BioStem Technologies stock traded down 0.93 during trading on Thursday, hitting 12.62. 41,400 shares of the stock were exchanged, compared to its average volume of 26,303. The stock’s fifty day moving average is 9.07 and its 200 day moving average is 9.27. The stock has a market cap of $205.55 million, a PE ratio of 32.05 and a beta of 0.03. BioStem Technologies has a 12 month low of 1.21 and a 12 month high of 15.50.
BioStem Technologies (OTCMKTS:BSEM – Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The company reported 0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of 0.12 by 0.18. The business had revenue of 74.49 million during the quarter, compared to the consensus estimate of 43.99 million. Sell-side analysts anticipate that BioStem Technologies will post 0.49 EPS for the current fiscal year.
BioStem Technologies Company Profile
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Featured Articles
- Five stocks we like better than BioStem Technologies
- How to Calculate Inflation Rate
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Using the MarketBeat Dividend Tax Calculator
- Jeff Brown’s Exegesis AI Stock Picks
- Using the MarketBeat Stock Split Calculator
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for BioStem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioStem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.